Microsoft moves into genetic-data

  • 5 June 2009

Microsoft Corporation has made a move into genetic data management, following its acquisition of Rosetta Inpharmatics LLC, a subsidiary of pharmaceutical firm Merck & Co.

The Rosetta technology will be used to add genetic and genomic data management abilities to Microsoft’s recently announced Amalga Life Sciences effort.

The agreement calls for Microsoft and Merck to collaborate on software to improve drug discovery and development. Financial details were not disclosed.

Link

Rosetta Inpharmatics LLC

Microsoft Amalga

 

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

NHS cyber security concerns raised about move to Windows 11

NHS cyber security concerns raised about move to Windows 11

Fears have been raised that the NHS could be hit by cyber security issues because organisations are not prepared to migrate to Windows 11.
Microsoft confirmed as Rewired 2025 co-headline sponsor

Microsoft confirmed as Rewired 2025 co-headline sponsor

Microsoft has been confirmed as the co-headline sponsor of Digital Health Rewired 2025, the UK’s biggest and best digital health conference. 
2025 predictions: Health tech suppliers on what’s in store

2025 predictions: Health tech suppliers on what’s in store

Digital Health News asked suppliers to share their predictions about what lies ahead for the sector in 2025.